SEC Form 4 · accession 0001171843-15-000174
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Gary Patou
Director
Period of report
Jan 7, 2015
Accepted (ET)
Jan 9, 2015 · 8:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jan 7, 2015 | M | 3,497 | $4.98 | A | 3,497 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $4.98 | Jan 7, 2015 | M | 3,497 | D | — | May 8, 2015 | Common Shares | 3,497 | 0 | D |
Explanation of responses
- F1The exercise price was converted from $6.07 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- F2The shares subject to the option fully vested on January 1, 2008.